EUVIMEDObjevte EUVIMED
MetaanalyseSystematische ÜbersichtÜbersichtsarbeitOpen access · CC BY 4.0

Efficacy and Safety of Lisdexamfetamine Versus Topiramate Versus Naltrexone/Bupropion in Individuals With Binge Eating Disorder: A Network Meta‐Analysis

Tamer Hodrob iD, Ibrahim Ismail, Alaaeddin Abusalameh, Celina R Andonie iD, Omar Ayesh, Hazem Ayesh iD

European Eating Disorders Review · 2026-03 · 34 (2) · 334-346

DOI: 10.1002/erv.70035 ↗

At a glance

Metaanalyse in European Eating Disorders Review, published online on 2025-09-22. Written by Tamer Hodrob and 5 co-authors. Institution: Faculty of Medicine, Al-Quds University, East Jerusalem, Palestine. Major MEDLINE topics: Naltrexone, Lisdexamfetamine Dimesylate, Topiramate, Binge-Eating Disorder. Cited 2 times so far (Crossref); 49 references. The full text is freely available (open access, CC BY 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objective

To compare the efficacy and safety of lisdexamfetamine, topiramate, and naltrexone/bupropion for treating binge eating disorder (BED) using network meta‐analysis.

Method

We systematically searched PubMed, Scopus, ClinicalTrials.gov, and Cochrane Central up to February 2025 for randomized controlled trials evaluating these medications versus placebo in adults with BED. Primary outcomes were changes in binge eating frequency and body weight; secondary outcomes included serious adverse events, discontinuation rates, and common side effects. A frequentist random‐effects network meta‐analysis was performed.

Results

Twelve trials ( n = 1988) met inclusion criteria. Both lisdexamfetamine (MD −1.61, 95% CI: −2.41 to −0.81) and topiramate (MD −1.63, 95% CI: −2.53 to −0.74) significantly reduced binge eating frequency versus placebo, with comparable efficacy. Topiramate produced the greatest weight loss (MD −5.5 kg), followed by lisdexamfetamine (−4.6 kg). Naltrexone/bupropion did not significantly reduce binge frequency (MD −2.07, 95% CI: −4.45 to 0.31). Lisdexamfetamine was associated with higher risks of dry mouth and gastrointestinal events. No significant increase in serious adverse events was observed for any medication.

Conclusions

Topiramate and lisdexamfetamine are effective for reducing binge episodes and weight in BED. Naltrexone/bupropion showed modest weight effects but lacked clear efficacy for binge reduction. These findings support topiramate and lisdexamfetamine as primary pharmacologic options for BED.

Subjects

MeSH terms (MEDLINE)

NaltrexoneLisdexamfetamine DimesylateTopiramateBinge-Eating DisorderBupropionHumansNetwork Meta-Analysis as TopicAdult

Author keywords

binge eating disorderlisdexamfetaminenaltrexone/bupropiontopiramateweight

Substances

NaltrexoneLisdexamfetamine DimesylateTopiramateBupropion

Authors and institutions

  • Faculty of Medicine, Al-Quds University, East Jerusalem, Palestine.
  • Department of Medical Laboratory Sciences, Al-Aqsa University, Gaza, Palestine.
  • Deaconess Health System, Evansville, Indiana, USA.

ORCID profiles: Tamer Hodrob, Celina R Andonie, Hazem Ayesh

Cite

APA

Hodrob, T., Ismail, I., Abusalameh, A., Andonie, C. R., Ayesh, O., & Ayesh, H. (2026). Efficacy and Safety of Lisdexamfetamine Versus Topiramate Versus Naltrexone/Bupropion in Individuals With Binge Eating Disorder: A Network Meta‐Analysis. European Eating Disorders Review, 34(2), 334-346. https://doi.org/10.1002/erv.70035

Vancouver

Hodrob T, Ismail I, Abusalameh A, Andonie CR, Ayesh O, Ayesh H. Efficacy and Safety of Lisdexamfetamine Versus Topiramate Versus Naltrexone/Bupropion in Individuals With Binge Eating Disorder: A Network Meta‐Analysis. European Eating Disorders Review. 2026;34(2):334-346. doi:10.1002/erv.70035

BibTeX
@article{Hodrob2026,
  author = {Hodrob, Tamer and Ismail, Ibrahim and Abusalameh, Alaaeddin and Andonie, Celina R and Ayesh, Omar and Ayesh, Hazem},
  title = {Efficacy and Safety of Lisdexamfetamine Versus Topiramate Versus Naltrexone/Bupropion in Individuals With Binge Eating Disorder: A Network Meta‐Analysis},
  journal = {European Eating Disorders Review},
  year = {2026},
  volume = {34},
  number = {2},
  pages = {334--346},
  doi = {10.1002/erv.70035}
}
Start for free →